Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

ClinicalTrials.gov ID: NCT02296541

Public ClinicalTrials.gov record NCT02296541. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of 3 Different HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) With MVA-CMDR Boosts in Healthy, HIV-1-Uninfected Adults

Study identification

NCT ID
NCT02296541
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
105 participants

Conditions and interventions

Conditions

Interventions

  • DNA Nat-B env Biological
  • DNA CON-S env Biological
  • DNA Mosaic env Biological
  • MVA-CMDR Biological
  • Placebo for DNA Nat-B env Biological
  • Placebo for DNA CON-S env Biological
  • Placebo for DNA Mosaic env Biological
  • Placebo for MVA-CMDR Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2014
Primary completion
Oct 31, 2016
Completion
Jul 5, 2020
Last update posted
Apr 23, 2023

2014 – 2020

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Alabama CRS Birmingham Alabama 35294
Bridge HIV CRS San Francisco California 94143
The Hope Clinic of the Emory Vaccine Center CRS Decatur Georgia 30030
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Boston Massachusetts 02115-6110
Fenway Health (FH) CRS Boston Massachusetts 02215-4302
Seattle Vaccine and Prevention CRS Seattle Washington 98109-1024

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02296541, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 23, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02296541 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →